%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2015-08-05T12:52-04:00
2015-08-05T12:52:01-04:00
2015-08-05T12:52:01-04:00
Adobe InDesign CC 2014 (Windows)
uuid:27e5b593-7adf-4126-bc78-4b0dee898eac
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:7f9c5979-4068-9842-9638-72c667069b73
proof:pdf
xmp.iid:f5afa97c-caa0-4940-b33c-3f3f2235b93e
xmp.did:5c249694-69e9-9242-9191-bddd62beacfa
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2014 (Windows)
/
2015-08-05T12:52-04:00
application/pdf
Adobe PDF Library 11.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
18 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
56.231 0 Td
[(Clinical Briefs in P)18.1(rimary Care)]TJ
ET
q
0 g
/GS1 gs
/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.03 Tc 7 0 0 7 40.75 363.24 Tm
(CLINICAL BRIEFS IN PRIMARY CARE)Tj
/T1_1 1 Tf
0 Tc 6 0 0 6 154.1484 363.24 Tm
(\231 )Tj
1.19 0 Td
( )Tj
-0.03 Tc -20.09 -1.167 Td
[(is published monthly by AHC Media, LLC. Copyright \251 2015)-30( )]TJ
0 -1.167 TD
[(AHC Media, LLC.)-30( )]TJ
/T1_2 1 Tf
8 0 0 8 40.75 339.24 Tm
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
/T1_2 1 Tf
0.03 Tw 0 -1.25 TD
(Editor:)Tj
/T1_1 1 Tf
0 Tw ( Stephen Brunton, MD)Tj
/T1_2 1 Tf
T*
(Associate Managing Editor:)Tj
/T1_1 1 Tf
[( Jonathan)-30( )]TJ
0.03 Tw T*
(Springston)Tj
0 Tw 6 0 0 6 40.75 295.24 Tm
[(This is an educational publication designed to present)-29.9( )]TJ
0 -1.167 TD
[(scientific information and opinion to health professionals,)-30( )]TJ
0 -1.167 TD
[(stimulate thought, and further investigation. It does not)-30( )]TJ
0 -1.167 TD
[(provide advice regarding medical diagnosis or treatment for)-30( )]TJ
T*
(any individual case. It is not intended for the layman.)Tj
0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
0 -1.167 TD
[(To reveal any potential bias in this publication, and in)-30( )]TJ
T*
[(accordance with Accreditation Council for Continuing)-30( )]TJ
0 -1.167 TD
[(Medical Education guidelines, Dr. Brunton \(editor\) reports)-30( )]TJ
0 -1.167 TD
[(he is a retained consultant for Abbott, AstraZeneca, Becton)-30( )]TJ
T*
[(Dickinson, Boehringer Ingelheim, Janssen, Lilly, Novartis, Novo)-30( )]TJ
0 -1.167 TD
[(Nordisk, Sanofi, and Teva; and he serves on the speakers)-30( )]TJ
0 -1.167 TD
[(bureau of AstraZeneca, Boehringer Ingelheim, Janssen, Lilly,)-29.9( )]TJ
T*
[(Novo Nordisk, and Teva. Dr. Kuritzky \(author\) reports he is)-30( )]TJ
0 -1.167 TD
[(a retained consultant for AbbVie, AstraZeneca, Boehringer)-29.9( )]TJ
0 -1.167 TD
[(Ingelheim, Bristol-Myers Squibb, Chelsea, Daiichi Sankyo,)-30( )]TJ
T*
[(Forest Pharmaceuticals, Janssen, Lilly, Novo Nordisk, Pfizer,)-30( )]TJ
0 -1.167 TD
[(and Sanofi. Ms. Coplin \(executive editor\), and Mr. Springston)-30( )]TJ
0 -1.167 TD
[(\(associate managing editor\) report no financial relationships)-30( )]TJ
T*
(relevant to this field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 46.125 165.734 326.99 re
S
/CS0 cs 0.1 scn
43.545 85.88 146.91 68.76 re
f
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 48.0448 142.9401 Tm
[(SUBSCRIBER INFORMA)92(TION)]TJ
-0.01 Tc 7 0 0 7 48.0448 132.6641 Tm
(Customer Service: 1-800-688-2421)Tj
/T1_1 1 Tf
6 0 0 6 48.0448 125.6641 Tm
(Email Address: jonathan.springston@ahcmedia.com)Tj
T*
(World Wide Web: AHCMedia.com)Tj
0 -1.917 TD
[(Address Correspondence to: AHC Media, One)-10( )]TJ
0 -1.167 TD
[(Atlanta Plaza, 950 East Paces Ferry Road NE, Suite)-10( )]TJ
T*
[(2850, Atlanta, GA 30326.)-10( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
81.64 49.558 70.72 32.442 re
W n
/GS1 gs
q 1 0 0 1 88.9838 67.8133 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 107.4452 61.2239 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 125.1715 63.7154 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 132.7822 63.9877 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 140.1476 63.8379 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
143.619 66.602 1.675 -6.63 re
143.619 59.971 m
145.403 68.453 m
145.403 67.963 145.036 67.555 144.45 67.555 c
143.892 67.555 143.524 67.963 143.524 68.453 c
143.524 68.971 143.906 69.365 144.464 69.365 c
145.036 69.365 145.39 68.971 145.403 68.453 c
f
q 1 0 0 1 150.6175 63.2117 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
1 w 10 M
/GS1 gs
q 1 0 0 1 36 613.5496 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 36 562.5496 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
/T1_3 1 Tf
0 Tc -0.001 Tw 9 0 0 9 49.5 737.0496 Tm
(Overall, long-term anticoagulation was )Tj
0 Tw -1.5 -1.2 Td
(associated with about an 80% reduction )Tj
0 -1.2 TD
(in recurrent venous thromboembolic )Tj
0 -1.2 TD
(events compared to short-term )Tj
T*
(anticoagulation \(30 events/1771 persons )Tj
T*
(vs 155 events/1765 persons, respectively\). )Tj
0 -1.2 TD
(Despite the con\037rmed risk reduction, )Tj
0 -1.2 TD
(clinicians must still take baseline bleeding )Tj
0 -1.2 TD
(risk into consideration, since the risk-)Tj
T*
(bene\037t balance shifts as bleeding risk )Tj
T*
(increases. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 78.0024 629.0496 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 36 599.5496 Tm
[(P)17.6(reventing R)17.6(ecurrence)-4.8( )]TJ
0 -1.143 TD
[(of Depression: Cognitive)-4.7( )]TJ
0 -1.143 TD
(Therapy or Medication?)Tj
/TT1 1 Tf
0 Tc 9 0 0 9 36 544.7495 Tm
[(SOURCE: K)17.5(uyken W)124(, et al. Effectiveness )]TJ
0 -1.2 TD
(and cost-effectiveness of mindfulness-based )Tj
T*
(cognitive therapy compared with maintenance )Tj
T*
(antidepressant treatment in the prevention of )Tj
T*
(depressive relapse or recurrence )Tj
12.826 0 Td
( )Tj
-12.826 -1.2 Td
(\(PREVENT\): A randomised controlled trial. )Tj
/TT2 1 Tf
T*
[(L)17.6(ancet)]TJ
/TT1 1 Tf
( 2015;386:63-73.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 36.6663 449.3495 Tm
(A)Tj
/T1_3 1 Tf
9 0 0 9 55.5592 460.1495 Tm
(fter an initial episode of depression, )Tj
T*
(unless preventive treatment is )Tj
-2.173 -1.2 Td
(initiated, recurrence is the rule rather )Tj
T*
(than the exception \(50-80%\). As a )Tj
T*
(result, national guidelines support )Tj
T*
(maintenance treatment, especially for )Tj
T*
(persons with demonstrated recurrence )Tj
T*
(or with other high-risk indicators \(e.g., )Tj
ET
/GS1 gs
q 1 0 0 1 214.008 416.7747 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 214.008 365.611 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 214.008 737.0496 Tm
[(history of bipolar disorder)111.1(, family history )]TJ
0 -1.209 TD
(of recurrences, or early age at initial )Tj
T*
(diagnosis\). The United Kingdom NICE )Tj
T*
(Guidelines endorse at least 2 years of )Tj
T*
(maintenance antidepressants when )Tj
T*
(depression is recurrent. )Tj
1.5 -1.209 Td
(PREVENT was a randomized, )Tj
-1.5 -1.209 Td
(controlled trial \(n = 424\) comparing )Tj
T*
(mindfulness-based cognitive )Tj
0 -1.209 TD
(therapy \(MBCT\) to antidepressant )Tj
0 -1.209 TD
(pharmacotherapy for prevention of )Tj
T*
(depression recurrence. Inclusion required )Tj
T*
(at least three prior episodes of major )Tj
T*
(depression. Study subjects randomized to )Tj
T*
[(MBCT had been on pharmacotherapy)92.1(, )]TJ
T*
(which was tapered/discontinued during )Tj
0 -1.209 TD
(the MBCT phase of treatment \(71% fully )Tj
0 -1.209 TD
(discontinued, 17% reduced dose, 13% )Tj
T*
(no dose reduction [total > 100% due to )Tj
T*
(rounding]\).)Tj
1.5 -1.209 Td
(Over a 24-month interval, slightly )Tj
-1.5 -1.209 Td
(fewer than half of the subjects experienced )Tj
T*
(relapse \(44-47%\), with no signi\037cant )Tj
T*
(difference demonstrable between MBCT )Tj
0 -1.209 TD
[(and pharmacotherapy)92.1(. )]TJ
1.5 -1.209 Td
(The comparable ef\037cacy of MBCT )Tj
-1.5 -1.209 Td
(and pharmacotherapy should prompt )Tj
0 -1.209 TD
(clinicians to offer patients treatment as per )Tj
T*
(their preference. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
10 0 0 10 282.0018 432.3566 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 214.008 402.7747 Tm
[(P)17.6(redicting Which P)35.7(atients)-4.9( )]TJ
0 -1.149 TD
[(with Non-alcoholic Fatty)-4.9( )]TJ
0 -1.149 TD
[(Liver Disease Will P)17.6(rogress)]TJ
/TT1 1 Tf
0 Tc 9 0 0 9 214.008 347.7291 Tm
(SOURCE: Bazick J, et al. Clinical model for )Tj
0 -1.209 TD
(NASH and advanced fibrosis in adult patients )Tj
T*
(with diabetes and NAFLD: Guidelines for refer)Tj
17.791 0 Td
(-)Tj
-17.791 -1.209 Td
(ral in NAFLD. )Tj
/TT2 1 Tf
(Diabetes Care)Tj
/TT1 1 Tf
10.855 0 Td
( 2015;38:1347-)Tj
-10.855 -1.209 Td
(1355.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 213.8007 273.5197 Tm
(T)Tj
/T1_3 1 Tf
-0.01 Tc 9 0 0 9 232.0795 284.3196 Tm
[(he language of progressive steps in)-10( )]TJ
0 -1.2 TD
[(liver disease used to be simpler: Y)86.1(ou)-10( )]TJ
-2.008 -1.209 Td
[(had cirrhosis, or you didn\222)37(t.)-10( )]TJ
1.5 -1.209 Td
[(But things have gotten much more)-10( )]TJ
-1.5 -1.209 Td
[(complicated. Non-alcoholic fatty liver)-10( )]TJ
0 -1.209 TD
[(disease \(NAFLD\) is now reported to be)-10( )]TJ
T*
[(the most common cause of chronic liver)-10( )]TJ
T*
[(disease in the United States, and is present)-9.9( )]TJ
0 -1.209 TD
[(in 50-75% of diabetics, thus representing)-10( )]TJ
0 -1.209 TD
[(as many as 18 million people among)-10( )]TJ
T*
(diabetics alone.)Tj
1.5 -1.209 Td
[(W)74(ere NAFLD to simply stay NAFLD,)-10( )]TJ
-1.5 -1.209 Td
[(we would have much less to discuss.)-10( )]TJ
T*
[(Unfortunately)92(, 10-22% of NAFLD)-10( )]TJ
T*
[(patients have a progressive type called)-10( )]TJ
T*
[(non-alcoholic steatohepatitis \(NASH\),)-9.9( )]TJ
0 -1.209 TD
[(which itself may progress to cirrhosis and)-10( )]TJ
0 -1.209 TD
[(hepatocellular carcinoma.)-9.9( )]TJ
1.5 -1.209 Td
[(One way to identify NAFLD patients)-10( )]TJ
-1.5 -1.209 Td
[(with NASH is to perform liver biopsy;)-10( )]TJ
T*
[(appraisal of the degree and pattern of)-9.9( )]TJ
T*
[(\037brosis seen on liver biopsy provides)-10( )]TJ
T*
[(grounds for staging of NASH. But since)-10( )]TJ
ET
/GS1 gs
q 1 0 0 1 392.016 545.8333 cm
0 0 m
165.984 0 l
S
Q
q 1 0 0 1 392.016 510.6617 cm
0 0 m
165.984 0 l
S
Q
BT
/GS0 gs
9 0 0 9 392.016 737.0496 Tm
[(there is risk, expense, and discomfort)-10( )]TJ
0 -1.219 TD
[(associated with this procedure,)-10( )]TJ
T*
[(identi\037cation of other biologic markers)-10( )]TJ
0 -1.219 TD
(indicative of NASH has been sought.)Tj
1.5 -1.219 Td
[(Bazick et al reported on the)-10( )]TJ
-1.5 -1.219 Td
[(development of a panel of markers that)-10( )]TJ
0 -1.219 TD
[(have suitable sensitivity and speci\037city to)-10( )]TJ
0 -1.219 TD
[(identify which patients with NAFLD are)-9.9( )]TJ
0 -1.219 TD
[(most likely to have NASH, potentially)-10( )]TJ
0 -1.219 TD
[(bene\037tting from referral for liver biopsy)-10( )]TJ
0 -1.219 TD
[(and con\037rmation of degree of \037brosis.)-10( )]TJ
0 -1.219 TD
[(The panel includes age, ethnicity)92(, body)-9.9( )]TJ
T*
[(mass index, waist:hip ratio, liver function)-10( )]TJ
T*
[(tests, international normalized ratio, serum)-10( )]TJ
T*
[(proteins, complete blood count, and serum)-10( )]TJ
T*
[(insulin levels, all of which are obtainable)-9.9( )]TJ
T*
(with minimum of patient inconvenience. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 550.4145 561.5048 Tm
<0084>Tj
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
-0.005 Tc 14 0 0 14 392.016 531.8333 Tm
[(T)175(ramadol for P)17.6(remature)-4.8( )]TJ
0.005 Tw 0 -1.155 TD
(Ejaculation)Tj
/TT1 1 Tf
0 Tc 0 Tw 9 0 0 9 392.016 492.6902 Tm
[(SOURCE: Kirby EW)123.2(, et al. T)155.5(ramadol for the )]TJ
0 -1.219 TD
(management of premature ejaculation: A timely )Tj
T*
[(systematic review)72.1(. )]TJ
/TT2 1 Tf
(Int J Impot Res)Tj
/TT1 1 Tf
12.516 0 Td
( 2015;27:121-)Tj
-12.516 -1.219 Td
(127.)Tj
/TT0 1 Tf
30.3235 0 0 30.3235 389.795 429.004 Tm
(P)Tj
/T1_3 1 Tf
-0.01 Tc 9 0 0 9 405.9269 439.804 Tm
[(remature ejaculation is reported to be)-10( )]TJ
0 -1.2 TD
[(the most common sexual dysfunction)-9.9( )]TJ
-1.546 -1.219 Td
[(among men, although it may not appear)-10( )]TJ
0 -1.219 TD
[(that way to clinicians since patients often)-10( )]TJ
T*
[(do not seek help for the problem.)-10( )]TJ
1.5 -1.219 Td
[(Since routine inquiry into sexual health)-10( )]TJ
-1.5 -1.219 Td
[(issues often does not occur)111(, and since there)-9.9( )]TJ
T*
[(are no FDA-approved medications to treat)-10( )]TJ
0 -1.219 TD
[(premature ejaculation, it is not surprising)-10( )]TJ
0 -1.219 TD
[(that patients fail to bring forward the)-10( )]TJ
0 -1.219 TD
[(problem. As late as 1998 \(the year of the)-10( )]TJ
0 -1.219 TD
[(advent of V)37(iagra\), 90% of impotent men)-10( )]TJ
0 -1.219 TD
[(reported they did not discuss their sexual)-10( )]TJ
0 -1.219 TD
[(health problem with a clinician, citing)-10( )]TJ
T*
[(1\) their complaint might be disregarded,)-10( )]TJ
T*
[(2\) there might not be any remedy)92(, and)-10( )]TJ
T*
[(3\) the clinician might be embarrassed by)-10( )]TJ
T*
(discussing such issues.)Tj
1.5 -1.219 Td
[(T)98(o date, selective serotonin reuptake)-10( )]TJ
-1.5 -1.219 Td
[(inhibitors \(SSRIs\) have been the most)-10( )]TJ
T*
[(commonly used effective treatment for)-10( )]TJ
T*
[(premature ejaculation. SSRIs have shown)-10( )]TJ
T*
[(ef\037cacy on both a scheduled and pro re)-9.9( )]TJ
T*
[(nata basis. Kirby et al recently reported)-10( )]TJ
T*
[(on the ef\037cacy of tramadol for premature)-10( )]TJ
0.01 Tw T*
(ejaculation.)Tj
0 Tw 1.5 -1.219 Td
[(Based on results from eight articles)-10( )]TJ
-1.5 -1.219 Td
[(published in peer)55(-reviewed journals,)-10( )]TJ
0 -1.219 TD
[(most of which were placebo-controlled)-10( )]TJ
0 -1.219 TD
[(or comparison trials to paroxetine \(the)-10( )]TJ
T*
[(most commonly used SSRI for premature)-10( )]TJ
0 -1.219 TD
[(ejaculation\), the authors conclude that)-10( )]TJ
0 -1.219 TD
[(on-demand doses of 25-50 mg tramadol)-10( )]TJ
0 -1.219 TD
[(administered 2-4 hours prior to intercourse)-10( )]TJ
0 -1.219 TD
[(is effective in prolonging vaginal)-10( )]TJ
0 -1.219 TD
[(ejaculatory latency time and compares well)-10( )]TJ
T*
(with SSRIs in head-to-head trials. )Tj
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 10 0 0 10 523.7929 44.9999 Tm
<0084>Tj
ET
endstream
endobj
23 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
10 0 obj
<>
endobj
22 0 obj
<>
endobj
24 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
11 0 obj
<>
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
12 0 obj
<>
endobj
13 0 obj
<>
endobj
15 0 obj
<>
endobj
16 0 obj
<>
endobj
40 0 obj
<>
endobj
41 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆"uDsF'OuOD'&2G'j~"7vG?j$O ?O'I?ɟ'$O ?O'I?ɟ'3,Ɵ?gYyV2ee*)U,S,XXVLbbY2Ų++*V(VTPXXQBbbE
ŊnL_//?R_/WU_W+*_WU_W+*_o7M7&o
o7M7&o
:zX.oز>*+zR9OS Mb
endstream
endobj
42 0 obj
<>stream
HtU TSW['}$E)E
"P"*^.UkQ)uURmqZR7z60sLOĞӞw}` <]
I%f7 [QH@XA}B xVA>7*!lݡunG@>AP</,7)/(֛L3 κ0X|ƪ|W.}xڟ_\TZ6t.j+Np瀸la/.w^\0b9l+Ne`P$Nꥵ190ډE+A$Afb J2+k[;{Q=G8xРaڐа#F=/oD36v\ 'M05qIo%LIM{;̬lgϙ[P8d~iYyEeUּh+V~k~n6n\Ϸn۾/w՞-_~oo:|_?Ni;{|q?{· pt$T`bR`>,Ű,U: